In last trading session, Tarsus Pharmaceuticals Inc (NASDAQ:TARS) saw 0.75 million shares changing hands with its beta currently measuring 0.95. Company’s recent per share price level of $50.00 trading at $0.03 or 0.06% at ring of the bell on the day assigns it a market valuation of $2.08B. That closing price of TARS’s stock is at a discount of -14.56% from its 52-week high price of $57.28 and is indicating a premium of 59.84% from its 52-week low price of $20.08. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.56 million shares which gives us an average trading volume of 633.57K if we extend that period to 3-months.

For Tarsus Pharmaceuticals Inc (TARS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.63 in the current quarter.

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) trade information

Upright in the green during last session for gaining 0.06%, in the last five days TARS remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $50.00 price level, adding 1.96% to its value on the day. Tarsus Pharmaceuticals Inc’s shares saw a change of -9.70% in year-to-date performance and have moved 1.52% in past 5-day. Tarsus Pharmaceuticals Inc (NASDAQ:TARS) showed a performance of -1.98% in past 30-days. Number of shares sold short was 7.65 million shares which calculate 11.23 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 62 to the stock, which implies a rise of 19.35% to its current value. Analysts have been projecting 58 as a low price target for the stock while placing it at a high target of 72. It follows that stock’s current price would drop -16.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -16.0% for stock’s current value.

Tarsus Pharmaceuticals Inc (TARS) estimates and forecasts

This year revenue growth is estimated to rise 102.09% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 71.62M for the same. And 4 analysts are in estimates of company making revenue of 89.63M in the next quarter. Company posted 27.61M and 40.81M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -66.60% during past 5 years.

Tarsus Pharmaceuticals Inc (NASDAQ:TARS)’s Major holders

Insiders are in possession of 8.28% of company’s total shares while institution are holding 103.03 percent of that, with stock having share float percentage of 112.33%. Investors also watch the number of corporate investors in a company very closely, which is 103.03% institutions for Tarsus Pharmaceuticals Inc that are currently holding shares of the company. RTW INVESTMENTS, LP is the top institutional holder at TARS for having 3.41 million shares of worth $92.75 million. And as of 2024-06-30, it was holding 9.0222 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 3.27 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.6368 of outstanding shares, having a total worth of $88.79 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.14 shares of worth $56.88 million or 2.96% of the total outstanding shares. The later fund manager was in possession of 980.96 shares on Mar 31, 2025 , making its stake of worth around $49.05 million in the company or a holder of 2.56% of company’s stock.